Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Patterson

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|July 4, 2019
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinibJorge J Castillo, Lian Xu, Joshua N Gustine, et al.
Blood Advances|April 15, 2026
Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cellsDominic Pizzarella, Amanda Kofides, John M Hatcher, et al.
Haematologica|June 24, 2021
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapyJoshua N Gustine, Shayna Sarosiek, Catherine A Flynn, et al.
British Journal of Haematology|February 18, 2009
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom MacroglobulinemiaXavier Leleu, Zachary R Hunter, Lian Xu, et al.
Blood Advances|November 8, 2018
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Nickolas Tsakmaklis, et al.
The New England Journal of Medicine|August 31, 2012
MYD88 L265P somatic mutation in Waldenström's macroglobulinemiaSteven P Treon, Lian Xu, Guang Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Lenalidomide and rituximab in Waldenstrom's macroglobulinemiaSteven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphomaAlessandra Tedeschi, Rebecca Auer, Francesco Autore, et al.
American Journal of Hematology|December 24, 2019
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemiaJorge J Castillo, Joshua N Gustine, Andrew Keezer, et al.
Hemasphere|July 22, 2021
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88<sup>L265P</sup> in Waldenström MacroglobulinemiaAmanda Kofides, Zachary R Hunter, Lian Xu, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|July 4, 2019
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinibJorge J Castillo, Lian Xu, Joshua N Gustine, et al.
Blood Advances|April 15, 2026
Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cellsDominic Pizzarella, Amanda Kofides, John M Hatcher, et al.
Haematologica|June 24, 2021
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapyJoshua N Gustine, Shayna Sarosiek, Catherine A Flynn, et al.
British Journal of Haematology|February 18, 2009
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom MacroglobulinemiaXavier Leleu, Zachary R Hunter, Lian Xu, et al.
Blood Advances|November 8, 2018
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemiaZachary R Hunter, Lian Xu, Nickolas Tsakmaklis, et al.
The New England Journal of Medicine|August 31, 2012
MYD88 L265P somatic mutation in Waldenström's macroglobulinemiaSteven P Treon, Lian Xu, Guang Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Lenalidomide and rituximab in Waldenstrom's macroglobulinemiaSteven P Treon, Jacob D Soumerai, Andrew R Branagan, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 4 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with non-IgM lymphoplasmacytic lymphomaAlessandra Tedeschi, Rebecca Auer, Francesco Autore, et al.
American Journal of Hematology|December 24, 2019
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemiaJorge J Castillo, Joshua N Gustine, Andrew Keezer, et al.
Hemasphere|July 22, 2021
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88<sup>L265P</sup> in Waldenström MacroglobulinemiaAmanda Kofides, Zachary R Hunter, Lian Xu, et al.
Pageof 11